Antitumor response and immunomodulatory effects of sub-microsecond irreversible electroporation and its combination with calcium electroporation
Author | Affiliation | |
---|---|---|
Novickij, Vitalij | ||
Date | Volume | Issue | Start Page | End Page |
---|---|---|---|---|
2019 | 11 | 11 | 1 | 18 |
In this work, we have investigated the feasibility of sub-microsecond range irreversible electroporation (IRE) with and without calcium electroporation in vivo. As a model, BALB/C mice were used and bioluminescent SP2/0 myeloma tumor models were developed. Tumors were treated with two separate pulsed electric field (PEF) pulsing protocols PEF1: 12 kV/cm 200 ns 500 (0.006 J/pulse) and PEF2: 12 kV/cm 500 ns 500 (0.015 J/pulse), which were delivered with and without Ca2+ (168 mM) using parallel plate electrodes at a repetition frequency of 100 Hz. Both PEF1 and PEF2 treatments reduced tumor growth and prolonged the life span of the mice, however, the PEF2 protocol was more e cient. The delay in tumor renewal was the biggest when a combination of IRE with calcium electroporation was used, however, we did not obtain significant di erences in the final mouse survival compared to PEF2 alone. Anti-tumor immune responses were also investigated after treatment with PEF2 and PEF2+Ca. In both cases the treated mice had enlarged spleens and increased spleen T cell numbers, lower percentages of suppressor cell subsets (conventional CD4+CD25+ Treg, CD4+CD25 DX5+ Tr1, CD8+DX5+, CD4+CD28, CD8+CD28), changed proportions of Tcm and Tef/Tem T cells in the spleen and increased amount of tumor cell specific antibodies in the sera. The treatment based on IRE was e ective against primary tumors, destroyed the tumor microenvironment and induced an anti-tumor immune response, however, it was not sufficient for complete control of tumor metastasis.
Journal | IF | AIF | AIF (min) | AIF (max) | Cat | AV | Year | Quartile |
---|---|---|---|---|---|---|---|---|
Cancers | 6.126 | 4.837 | 4.837 | 4.837 | 1 | 1.266 | 2019 | Q1 |
Journal | IF | AIF | AIF (min) | AIF (max) | Cat | AV | Year | Quartile |
---|---|---|---|---|---|---|---|---|
Cancers | 6.126 | 4.837 | 4.837 | 4.837 | 1 | 1.266 | 2019 | Q1 |
Journal | Cite Score | SNIP | SJR | Year | Quartile |
---|---|---|---|---|---|
Cancers | 3.4 | 1.445 | 1.938 | 2019 | Q3 |